We have been wondering about Biosimilars on the forum especially lately about Benepali. Found some useful info here.
Good information about Biosimilars: We have been... - NRAS
Good information about Biosimilars
Actually lots of good information about Ra meds and everything else. You may already be familiar with this site.?
I assume that you have also looked at the useful information on the NRAS website and specifically about biosimilars?
I have and found it very biased in many ways.
It would be useful if you could feedback to NRAS why you think that? It may be that it is written in a way to reassure people who are anxious, but in the process it is minimising the problems?
I think you are right when you are anxious you do need good news and belief in something and support from authorities. True enough this information does help many but once you learn more from research on many different angles you can accumulate knowledge that you can apply on your individual situation when planning your treatment, hopefully with a good doctor(s). Rawarrior is in my view gives more balanced information and good links that help RA pas to keep in touch with a more holistic current picture of RA and treatments.
I'm just having a read of it now, Agoodlife (formerly Simba1992).
It presents quite well, in style and layout, and the question format is a good one for covering the ground. There is one part which fails I think, a box which gives some explanatory text -
Separate cell lines: “Follow-on manufacturers do not have access to the originator’s molecular clone and original cell bank, nor to the exact fermentation and purification process, nor to the active drug substance, although they do have access to the commercialized innovator product.”
I'm not very clear as to whether this is another quotation from the FDA, so my first complaint is lack of a reference to the source of the quote. Second, I'm not sure what "commercialized innovator product" means in this context. Is it in effect what I would call the contents of the packaged syringes supplied to the patient?
Then too I wonder about the reference to "active drug substance". I'm guessing this might be what comes out of the manufacturing process before being mixed up with (probably inert) dilutants to allow successful dispensing via syringe? Not very clear however.
I found the survey box a bit annoying. It presents a useful chance for readers to give feedback, offering some interactivity, but obviously it should be treated with extreme caution, and might be offputting to some.
Cheers